Type 2 diabetes mellitus (T2DM) is a well-known risk factor for cardiovascular disease. Various drugs including DPP4 inhibitors with different pharmacologic profile are being used in patients with type 2 diabetes for improving glycaemic control. Cardiovascular (CV) safety is one of the important aspects while selecting the glucose lowering therapies. Teneligliptin is a DPP4 inhibitor, approved recently for the management of type 2 diabetes mellitus.
The purpose of the article is to evaluate the QT interval prolongation of Teneligliptin in type 2 diabetic patients. As per the USFDA guidance, initially QTc studies in animals should be performed. The biggest drawback of Teneligliptin observed in in-vitro and in vivo studies is that it produces QTc interval prolongation in the ECG. If the QT interval prolongation with a drug is witnessed in pre-clinical studies, it should be investigated in…
